Minette-Joëlle Zeukeng

Suggest Changes
Learn More
In his letter to the Editor, Braillon [1] argues that the use of surrogate endpoints and delays in post-marketing studies can result in the use of ineffective and harmful drugs. While our study did(More)
  • 1